RadioGel™ Cancer Therapy
RadioGel is an yttrium-90 (90Y) based injectable Precision Radionuclide Therapy (PRnT) device
for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
cancerous tumors by placing a radioactive isotope directly inside the treatment
area using the company’s proprietary hydrogel technology.
Learn more
RadioGel™ – Cancer therapy for humans.
Radiogel™ is a hydrogel liquid containing tiny Yttrium-90 (Y-90) phosphate microparticles that may be administered directly into a tumor.
The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range
beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
Learn More
IsoPet® – Cancer therapy for animals
The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at
the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.
Learn More
“This filing was on the heels of another milestone for Vivos, as the US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles."
( Mike Korenko, Sc.D • CEO • President | September 14, 2022 Press Release )
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™
September 14, 2022
Richland WA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA (16309: 17/943,311) and internationally (16389: PCT/US22/43274) under The Patent Cooperation Treaty (PCT).
Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component. Our objectives were to maximize production
output, to refine our specifications to yield the optimum gelation and resorption characteristics, to demonstrate reproducibility and to ensure that any residual solvents were minor and well
below the FDA specifications limits for human therapy.
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
